20110123535Use of Nogo Receptor-1 (NGR1) for Promoting Oligodendrocyte Survival - The invention provides methods of treating diseases, disorders or injuries involving oligodendrocyte death, demyelination and dysmyelination, including spinal cord injury, by the administration of an NgR1 antagonist.05-26-2011